Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Invesco Nasdaq Biotechnology ETF (IBBQ)

Invesco Nasdaq Biotechnology ETF (IBBQ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Biotech ETFs Pop on M&A Resurgence

2023 could be a year of heightened biotech dealmaking activity

GSK : 44.11 (-0.09%)
NVS : 99.64 (+0.58%)
PFE : 28.12 (+1.26%)
MRK : 129.62 (-0.58%)
AMGN : 304.03 (+1.24%)
GILD : 64.96 (-0.76%)
VRTX : 421.05 (+2.64%)
IBB : 132.29 (-0.74%)
SGEN : 228.74 (-0.07%)
RXDX : 199.92 (+0.09%)
XBI : 88.47 (-2.17%)
SBIO : 34.46 (-1.04%)
ETFs in Focus on Sanofi and Regeneron's COPD Drug Data

Shares of drugmakers Sanofi and Regeneron surged more than 6% on Mar 23 on COPD drug data.

REGN : 957.68 (-1.27%)
SNY : 50.12 (+1.11%)
IBB : 132.29 (-0.74%)
BBH : 163.43 (-0.25%)
IBBQ : 21.89 (-0.18%)
PINK : 29.30 (-1.68%)
Is Biotech Immunocore About To Make A 25% Price Move?

Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher.

IMCR : 60.74 (-0.49%)
AMGN : 304.03 (+1.24%)
GILD : 64.96 (-0.76%)
REGN : 957.68 (-1.27%)
VRTX : 421.05 (+2.64%)
MRNA : 121.37 (+0.25%)
EXAS : 60.40 (-1.64%)
ARKK : 44.38 (-2.57%)
LLY : 777.35 (-0.05%)
GSK : 44.11 (-0.09%)
IBBQ : 21.89 (-0.18%)
Should You Buy Beaten-Down Biotech Stocks & ETFs?

We highlight 4 ETFs that have started rebounding after a brutal sell-off

AMGN : 304.03 (+1.24%)
GILD : 64.96 (-0.76%)
VRTX : 421.05 (+2.64%)
IBB : 132.29 (-0.74%)
TDOC : 12.26 (-4.81%)
XBI : 88.47 (-2.17%)
CRSP : 53.12 (-4.34%)
ARKG : 24.55 (-2.66%)
IBBQ : 21.89 (-0.18%)
Pharma & Biotech ETFs at One-Month High: Here's Why

Pharma and biotech ETFs are in great shape and are trading at a one-month high level.

CNCR : 15.42 (-2.34%)
BBC : 27.61 (-1.74%)
PJP : 79.75 (+0.69%)
XPH : 41.00 (+0.69%)
PBE : 64.03 (-0.19%)
IEIH : 34.13 (unch)
GNOM : 10.26 (-1.35%)
GERM : 17.50 (-4.20%)
IBBQ : 21.89 (-0.18%)
Analysts Predict 59% Gains Ahead For The Holdings of IBBQ

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and...

IBBQ : 21.89 (-0.18%)
Implied IBBQ Analyst Target Price: $31

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and...

IBBQ : 21.89 (-0.18%)
IBBQ's Underlying Holdings Could Mean 48% Gain Potential

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and...

IBBQ : 21.89 (-0.18%)
Analysts Expect IBBQ Will Reach $32

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and...

IBBQ : 21.89 (-0.18%)
Analysts Anticipate IBBQ To Hit $32

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and...

IBBQ : 21.89 (-0.18%)

Barchart Exclusives

Teva Pharmaceuticals Stock Has Unusual Call Options Activity After Its Q1 Results
Teva Pharmaceuticals, the generic drug maker, posted good Q1 results today, reaffirming its forecast for significant free cash flow in 2024. That led to unusual call options activity based on a Barchart report. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar